Shukra Pharmaceuticals Limited (BOM:524632)

Market Cap	11.93B
Revenue (ttm)	393.99M
Net Income (ttm)	101.19M
Shares Out	437.88M
EPS (ttm)	0.18
PE Ratio	148.89
Forward PE	n/a
Dividend	0.10 (0.36%)
Ex-Dividend Date	Sep 23, 2024

Volume	878,164
Average Volume	409,276
Open	28.92
Previous Close	28.36
Day's Range	27.80 - 28.92
52-Week Range	5.75 - 28.92
Beta	0.32
RSI	79.46
Earnings Date	Aug 12, 2025

About Shukra Pharmaceuticals

Shukra Pharmaceuticals Limited develops, manufactures, markets, and exports various drugs and dosage forms in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti tuberculosis, vitamin products, anti allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antib...

• Industry: Pharmaceutical Preparations
• Founded: 1993
• Employees: 182
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524632

Financial Performance

In 2024, Shukra Pharmaceuticals's revenue was 367.94 million, a decrease of -51.88% compared to the previous year's 764.66 million. Earnings were 95.75 million, a decrease of -48.35%.